EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial

Sang Kun Lee iD, Sang Ahm Lee iD, Seung Bong Hong iD, Yong Won Cho iD, Guillermo Castilla-Fernández, Miguel M Fonseca, Joana Moreira, Helena Gama, Joerg Holenz

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13802 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Sang Kun Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Seoul National University Hospital, Seoul, South Korea. Hauptthemen laut MEDLINE: Dibenzazepines, Asian People, Anticonvulsants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A post hoc analysis of data from Asian patients included in the study BIA‐2093‐304 was conducted to evaluate the long‐term safety/tolerability and efficacy of adjunctive eslicarbazepine acetate (ESL) in adult Asian patients with refractory focal seizures. Part I was a randomized controlled trial, in which patients received ESL (800 or 1200 mg once daily [QD]) or placebo, assessed over a 12‐week maintenance period. Patients completing Part I could enter two open‐label extension periods (Part II, 1 year; Part III, ≥2 years), during which all received ESL (400–1600 mg QD). Safety/tolerability was assessed by evaluating treatment‐emergent adverse events (TEAEs). Efficacy assessments included responder and seizure freedom rates. The safety population included 125, 92, and 23 Asian patients in Parts I, II, and III, respectively. Incidence of ESL‐related TEAEs was 61.3%, 45.7%, and 17.4% during Parts I, II, and III, respectively. ESL‐related TEAEs (most commonly, dizziness, somnolence, and headache) were consistent with ESL's known safety profile. During Part I, responder rates were higher with ESL 800 (41.7%) and 1200 mg QD (44.4%) versus placebo (32.6%), although not statistically significant. Seizure freedom rates with ESL 800 (5.5%) and 1200 mg QD (11.1%) were also higher versus placebo (0%) ( p < 0.05 for ESL 1200 mg QD versus placebo). At the end of Part II, responder and seizure freedom rates were 60.3% and 14.7%, respectively. In summary, adult Asian patients with refractory focal seizures were responsive to treatment with ESL as adjunctive therapy and generally showed treatment tolerance well for up to 3 years. No new/unexpected safety findings were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DibenzazepinesAsian PeopleAnticonvulsantsHumansAdultMaleFemaleMiddle AgedTreatment OutcomeSeizuresYoung AdultDouble-Blind MethodDrug Therapy, CombinationDrug Resistant EpilepsyEpilepsies, PartialAdolescentAged

Substanzen

eslicarbazepine acetateDibenzazepinesAnticonvulsants

Autor:innen und Institutionen

  • Seoul National University Hospital, Seoul, South Korea.
  • Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Samsung Medical Center, Sungkyunkwan University School of Medicine and Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Seoul, Korea.
  • Keimyung University Dongsan Medical Center, Daegu, South Korea.
  • BIAL R&D Investments, S.A, Porto, Portugal.
  • BIAL - Portela & Cª, S.A, Coronado, Portugal.

ORCID-Profile: Sang Kun Lee, Sang Ahm Lee, Seung Bong Hong, Yong Won Cho

Zitieren

APA

Lee, S. K., Lee, S. A., Hong, S. B., Cho, Y. W., Castilla-Fernández, G., Fonseca, M. M., Moreira, J., Gama, H., & Holenz, J. (2024). Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial. Clinical and Translational Science. https://doi.org/10.1111/cts.13802

Vancouver

Lee SK, Lee SA, Hong SB, Cho YW, Castilla-Fernández G, Fonseca MM, et al. Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial. Clinical and Translational Science. 2024. doi:10.1111/cts.13802

BibTeX
@article{Lee2024,
  author = {Lee, Sang Kun and Lee, Sang Ahm and Hong, Seung Bong and Cho, Yong Won and Castilla-Fernández, Guillermo and Fonseca, Miguel M and Moreira, Joana and Gama, Helena and Holenz, Joerg},
  title = {Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13802}
}
Kostenlos starten →